Vikram V Shanbhogue
Overview
Explore the profile of Vikram V Shanbhogue including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
513
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Muollo V, Hvid L, Shanbhogue V, Steinhauser V, Caporossi D, Dimauro I, et al.
Arch Osteoporos
. 2024 Dec;
20(1):5.
PMID: 39729186
Purpose: This study aimed to compare the effects of 12-week of power training (PWT), an explosive form of strength training, on bone microarchitecture, estimated bone strength, and markers in mobility-limited...
2.
Hansen S, Wernberg C, Gronkjaer L, Jacobsen B, Di Caterino T, Krag A, et al.
JBMR Plus
. 2023 Mar;
7(3):e10714.
PMID: 36936359
There is controversy regarding the association between nonalcoholic fatty liver disease (NAFLD) and osteoporosis. Our study aim was to assess bone mineral density (BMD) in patients with biopsy-proven NAFLD and...
3.
Hansen S, Shanbhogue V, Jorgensen N, Beck-Nielsen S
Calcif Tissue Int
. 2019 Feb;
104(6):591-598.
PMID: 30710161
Aspects of bone remodeling have only been scarcely studied in X-linked hypophosphatemia (XLH). In this cross-sectional controlled study, we assessed biochemical indices of bone remodeling and sclerostin in 27 adult...
4.
Shanbhogue V, Hansen S, Frost M, Brixen K, Hermann A
Lancet Diabetes Endocrinol
. 2017 Sep;
5(10):769-770.
PMID: 28938995
No abstract available.
5.
Shanbhogue V, Hansen S, Frost M, Brixen K, Hermann A
Lancet Diabetes Endocrinol
. 2017 May;
5(10):827-838.
PMID: 28546096
Type 1 and type 2 diabetes are generally accepted to be associated with increased bone fracture risk. However, the pathophysiological mechanisms of diabetic bone disease are poorly understood, and whether...
6.
Shanbhogue V, Stoving R, Frederiksen K, Hanson S, Brixen K, Gram J, et al.
Eur J Endocrinol
. 2017 Mar;
176(6):685-693.
PMID: 28289103
Objective, Design And Methods: Roux-en-Y gastric bypass (RYGB) has proved successful in attaining sustained weight loss but may lead to metabolic bone disease. To assess impact on bone mass and...
7.
Shanbhogue V, Finkelstein J, Bouxsein M, Yu E
J Clin Endocrinol Metab
. 2016 Jun;
101(8):3114-22.
PMID: 27243136
Context: The clinical consequences of insulin resistance and hyperinsulinemia on bone remain largely unknown. Objective: The objective of the study was to evaluate the effect of insulin resistance on peripheral...
8.
Shanbhogue V, Brixen K, Hansen S
J Bone Miner Res
. 2016 Feb;
31(8):1541-9.
PMID: 26896351
Although projections from cross-sectional studies have shown that bone loss leading to osteoporosis begins around menopause in women and later in life in men, this has not been examined longitudinally...
9.
Shanbhogue V, Hansen S, Frost M, Jorgensen N, Hermann A, Henriksen J, et al.
Eur J Endocrinol
. 2015 Nov;
174(2):115-24.
PMID: 26537860
Objective And Design: Patients with type 2 diabetes mellitus (T2D) have an increased fracture risk despite a normal or elevated bone mineral density (BMD). The aim of this cross-sectional in...
10.
Shanbhogue V, Mitchell D, Rosen C, Bouxsein M
Lancet Diabetes Endocrinol
. 2015 Sep;
4(2):159-73.
PMID: 26365605
Substantial evidence shows that skeletal fragility should be considered among the complications associated with type 2 diabetes. Individuals with type 2 diabetes have increased fracture risk, despite normal bone mineral...